放射治疗在肝细胞癌（HCC）的治疗中日益被用作单独治疗或与全身治疗联合使用。立体定向身体放射治疗（SBRT）会直接（通过双链断裂）及间接（通过血管床损伤或促进抗肿瘤免疫）导致细胞死亡。可惜的是，细胞死亡的效果并非即时，需要时间。
适应症：HCC - Hepatocellular Carcinoma
入组条件
纳入标准
- Patients aged ≥ 18 years old
- Eastern Cooperative Oncology Group (ECOG) performance 0 to 1
- Confirmed diagnosis of Hepatocellular carcinoma (HCC)
- Tumour size ≥ 3cm
- Patients planning on undergoing Stereotactic Body Radiation Therapy (SBRT) for HCC
- Prior radiofrequency ablation at a different site, or prior surgery are eligible
- Child-Pugh A liver function
- Life expectancy longer than 12 weeks
- At least one measurable treatment lesion according to RECIST 1.1
- Written informed consent must be obtained prior to any study related procedures
- Adequate haematological function (Hemoglobin ≥ 8.5g/dL; Platelet Count ≥ 75x109/L; Antenatal Care ≥ 1.5x109/L; international normalised ratio ≤ 1.5)
- Adequate hepatic function (albumin ≥ 28g/l; Bilirubin ≤ 1.5xULN; Alanine transaminase \< 5 times upper limit normal)
- Adequate renal function (serum creatinine ≤ 1.5 times the upper limit of normal range; Sodium ≥ 130mmol/L; Potassium ≥ 3.0mmol/L)
- Able to read, understand and provide written consent
排除标准
- Histology shows sarcomatoid HCC, fibrolamellar HCC, mixed cholangiocarcinoma-hepatocellular carcinoma
- Presence of other malignancy than HCC within 5 years from diagnosis of HCC
- Prior Transarterial chemoembolization (TACE) within 3 months
- Previous radiotherapy to the abdomen
- Previous yttrium-90 chemoembolization
- Repetitive history of non-healing wounds or ulcers within 2 months of inclusion
- Pregnant or lactating females at any time during the study
- Active autoimmune disease requiring systemic therapy in the past 2 years
- Diagnosis of immunodeficiency (including Human Immunodeficiency Viruses)
- Patients with coagulopathy or on anticoagulant will be excluded from liver biopsy
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。